Navigation Links
Ulthera Launches New Aesthetic Clinical Indication - Treatment of the Decolletage - in Asia
Date:7/3/2012

MESA, Ariz., July 3, 2012 /PRNewswire/ -- Ulthera, Inc. – a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology – today announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area – also known as the decolletage or decollete.

The Ulthera System – which combines time-honored ultrasound imaging with focused ultrasound therapy in a procedure known as Ultherapy – has been used in many Asian countries to treat the face and neck since 2008. The new decolletage indication will utilize the System's same technology to encourage the natural formation of collagen and elastin on the chest – just as with the face and neck – giving it the ability to lift tissue. For the decolletage, this lifting effect can result in a gradual reduction of chest wrinkles over three months, with continued improvement possible for up to six months post-procedure.

"The global demand for safe and effective non-invasive procedures is rapidly growing. This is why Ulthera has made significant investments in clinical development to qualify our ultrasound platform technology for a host of medical and off-face aesthetic indications," said Matthew Likens, president and CEO of Ulthera. "Launching the decolletage treatment in Asia is just the tip of the iceberg. We anticipate an exciting second half of 2012 with even more international indications on the horizon as well as additional countries where System clearance is anticipated."

Starting July 3, 2012, Ulthera will be initiating a multi-country tour in Asia to introduce the new clinical indication to practitioners. For more information on the tour, contact Candice Wong at c.wong@ulthera.com or +852-9650-1505.

The Ulthera System is cleared by the U.S. FDA for use in a non-invasive treatment of the face to lift the eyebrow to achieve a desired aesthetic effect. The new clinical indication to treat the decolletage will not be commercially available in all Asian countries, including those that do not currently offer Ultherapy as well as Singapore and Hong Kong where the System is only cleared to treat the face.  

About Ulthera
Ulthera, Inc. is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company backed by top tier venture capital firms, New Enterprise Associates and Apposite Capital. For more information, visit www.ultherapy.com.

 


'/>"/>
SOURCE Ulthera, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bulgaria Launches Development of National Hepatitis Plan
2. Fidelitas Launches Unique Methadone Documentation and Dispensing System in Canada
3. Mylan Launches Thiamine Hydrochloride Injection
4. PeriGen, Inc. Launches Consumer Safety Campaign to Raise Awareness of Dangerous Birth Complication
5. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
6. Konica Minolta Sensing America Launches Spanish Website in Support of Growing Demand In Latin American Countries
7. The Michael J. Fox Foundation Launches The $14 Million-Edmond J. Safra Core Programs for PD Research
8. Lifescript Launches New Online Asthma Health Center
9. AUA Foundation Launches Campaign to Address Stigma of Overactive Bladder
10. Smith & Nephew launches two plating systems for foot and ankle surgeons at AOFAS annual meeting in San Diego
11. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
Breaking Medicine Technology:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):